Pharmacist-Led Care for Diabetes

Overseen by Kathryn E. Callahan, MD

Age: 65+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a program where a pharmacist helps older adults with type 2 diabetes manage their condition. The pharmacist works with the patient's doctor to adjust medications based on regular check-ups. The goal is to ensure the patient's diabetes care meets recommended guidelines.

Research Team

Kathryn E. Callahan, MD

Principal Investigator

Atrium Health Wake Forest Baptist Health

Eligibility Criteria

This trial is for older adults with Type 2 Diabetes who are taking certain diabetes medications, have had a specific level of blood sugar control in the past two years, and can communicate in English by phone. They must be part of a specific healthcare organization and not have severe hearing loss or dementia.

Inclusion Criteria

Your average blood sugar level (HbA1c) has been less than 7.5% in the last 2 years.

Attributed to a Atrium Health Wake Forest Baptist-affiliated Accountable Care Organization

I am currently using insulin or sulfonylurea for my Type 2 Diabetes.

Exclusion Criteria

I have been diagnosed with Alzheimer's disease or related dementia.

I do not speak English fluently.

I do not have a phone number for follow-up contacts.

Treatment Details

Interventions

• Pharmacist-Led Optimization Intervention (Behavioral Intervention)

Trial Overview The study tests if a pharmacist-led program can improve diabetes care for older adults by adjusting their medication to meet guidelines. Participants will work with pharmacists alongside their doctors and undergo routine bloodwork as part of the management program.

Participant Groups

Group I: Active Intervention Experimental Treatment 1 Intervention

Subjects are mailed Information about Type 2 Diabetes Mellitus (T2DM) Guidelines and Appointment Information (Face to face \[F2F\] or Telehealth). They attend up to 3 pharmacist visits, depending on if they reach target glucose levels. And they attend interviews. They also have month 6 follow up.

Group II: Active Decliners Active Control 1 Intervention

Subjects who decline intervention. Standard of care treatment with month 6 follow up.

Group III: Control Active Control 1 Intervention

Subjects in this arm will receive standard of care treatment with no intervention. They will receive month 6 follow up.

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials

1,432

Recruited

2,506,000+